Lymphocytes, Tumor-Infiltrating

• 

  Subject Areas on Research

  • 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. 
  • A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 
  • A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. 
  • Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
  • Adoptive immunotherapy for malignant glioma. 
  • An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. 
  • Analysis of lymphocytic infiltration in uveal melanoma. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 
  • Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. 
  • B cells and cancer. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. 
  • Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. 
  • CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. 
  • CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. 
  • CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. 
  • Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. 
  • Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. 
  • Combination gene therapy for liver metastasis of colon carcinoma in vivo. 
  • Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. 
  • Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. 
  • Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. 
  • Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. 
  • Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). 
  • Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. 
  • Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. 
  • Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. 
  • ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. 
  • Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. 
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. 
  • Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma. 
  • Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability. 
  • Going to extremes: determinants of extraordinary response and survival in patients with cancer. 
  • Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma. 
  • Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck. 
  • Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro. 
  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy. 
  • Immunotherapy for gynaecological malignancies. 
  • Immunotherapy of malignant brain tumors. 
  • Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. 
  • Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. 
  • Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. 
  • Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. 
  • Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma. 
  • Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. 
  • Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. 
  • Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. 
  • LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. 
  • Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages. 
  • Leukocyte composition of human breast cancer. 
  • Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. 
  • Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. 
  • Lymphoma-infiltrating immune cells. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. 
  • Metabolic Barriers to T Cell Function in Tumors. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity. 
  • Nutrients and the microenvironment to feed a T cell army. 
  • OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential. 
  • Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. 
  • Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. 
  • Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. 
  • PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. 
  • PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. 
  • Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. 
  • Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. 
  • Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Protocol for the isolation of CD8+ tumor-infiltrating lymphocytes from human tumors and their characterization by single-cell immune profiling and multiome. 
  • Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 
  • Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. 
  • Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. 
  • Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. 
  • Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. 
  • SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. 
  • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. 
  • Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. 
  • Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. 
  • Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. 
  • Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 
  • Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. 
  • Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: A retrospective cohort study. 
  • T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. 
  • T cell stemness and dysfunction in tumors are triggered by a common mechanism. 
  • T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. 
  • T cells in ovarian cancer. 
  • T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. 
  • TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. 
  • Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 
  • Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. 
  • The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. 
  • The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 
  • The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • The role for interleukin-12 therapy of cutaneous T cell lymphoma. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. 
  • Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. 
  • Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. 
  • Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. 
  • Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. 
  • Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. 
  • Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology